HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metallo-naphthalocyanines as photothermal sensitisers for experimental tumours: in vitro and in vivo studies.

AbstractBACKGROUND AND OBJECTIVES:
Photothermal sensitisation has been recently proposed as a novel approach for the treatment of solid tumours through the development of a therapeutic modality named photothermal therapy (PTT). The technique involves the use of high power pulsed laser irradiation and photosensitising agents with especially short lifetime (in the subnanosecond range) in the electronically excited states. This study aims to investigate the molecular features of the photosensitiser which optimise the photothermal activity.
STUDY DESIGN/MATERIALS AND METHODS:
Two octabutoxy-naphthalocyanines centrally coordinated with Pd(II) or Pt(II) ions were prepared by chemical synthesis and tested for their affinity and photothermal sensitisation activity toward a selected tumour cell line, namely B78H1 amelanotic melanoma. Irradiations were performed by using a Ti:sapphire laser operated in a pulsed regime (10 Hz, 30 nanosecond pulses, 120 mJ) at 809 nm (Pt) or 826 nm (Pd). The subcellular distribution pattern of the photosensitiser was also assessed by optical microscopy, while the nature of the photoinduced cell damage was determined by scanning electron microscopy. The results thus obtained provided a basis for subsequent in vivo studies, aimed at defining the phototherapeutic efficiency of the two metallo-naphthalocyanines: the photosensitisers were i.v. injected into C57BL/6 mice bearing a subcutaneously transplanted amelanotic melanoma and at 24 hours post-injection the tumour area was irradiated by the Ti:sapphire laser using the same protocol as above detailed.
RESULTS:
Both naphthalocyanines exhibited a high affinity for the amelanotic melanoma cells. The subcellular distribution pattern was modulated by the incubation time: after 48 hours incubation with 7.7 microM Pd- and Pt derivatives, the naphthalocyanine appeared to localise in specific sites with a gradual formation of aggregated clusters. Subsequent irradiation of the naphthalocyanine-loaded cells caused an extensive cell death; the photoinduced damage, as observed at the scanning electron microscope, mainly consisted in the formation of large endocellular holes consequent to the loss of cytoplasmic material. This scenario is typical of photothermal sensitisation processes. Lastly, both metallo-naphthalocyanines, and in particular the Pd(II) derivative, promoted an important response by the amelanotic melanoma, when the neoplastic tissue was irradiated by the pulsed Ti:sapphire laser. In certain cases, the photothermal treatment appeared to be curative. In all cases, the in vivo photodamage was confined within the tumour area with no detectable involvement of the perilesional tissues.
CONCLUSION:
PTT appears to act very efficiently at least on subcutaneous tumours. The technique can be used either in combination with photodynamic therapy (PDT) or as an alternative to PDT in those cases where the latter modality displays a limited efficacy, such as in the treatment of pigmented or poorly vascularised tumours.
AuthorsMonica Camerin, Santi Rello-Varona, Angeles Villanueva, Michael A J Rodgers, Giulio Jori
JournalLasers in surgery and medicine (Lasers Surg Med) Vol. 41 Issue 9 Pg. 665-73 (Nov 2009) ISSN: 1096-9101 [Electronic] United States
PMID19790243 (Publication Type: Journal Article)
CopyrightCopyright 2009 Wiley-Liss, Inc.
Chemical References
  • Metalloporphyrins
  • Organometallic Compounds
  • palladium 5,9,14,18,23,27,32,36-octabutoxynaphthalocyanine
  • Platinum
  • Palladium
Topics
  • Animals
  • Cell Culture Techniques
  • Cell Line, Tumor
  • Female
  • Laser Therapy
  • Melanoma, Amelanotic (pathology, radiotherapy)
  • Metalloporphyrins (therapeutic use)
  • Mice
  • Mice, Inbred C57BL
  • Neoplasm Transplantation
  • Organometallic Compounds (therapeutic use)
  • Palladium
  • Photochemotherapy (methods)
  • Platinum
  • Skin Neoplasms (pathology, radiotherapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: